Ascendis Pharma (ASND) Q3 2024 earnings summary

Executive summary

• Achieved strong clinical and commercial progress across all three rare endocrinology programs, with pivotal data supporting potential blockbuster status for each.

• SkyTrofa maintained a leading position in the U.S. pediatric growth hormone market, with significant year-over-year demand growth and ongoing label expansion efforts.

• YorviPath prepared for imminent U.S. launch with product availability expected mid-January 2025, robust ex-U.S. uptake, and expanded commercial infrastructure.

• TransCon CNP pivotal data in achondroplasia exceeded benchmarks, with NDA submission to FDA planned for Q1 2025 and MAA to EMA in Q3 2025.

• Entered a major collaboration with Novo Nordisk to develop once-monthly GLP-1 therapies for obesity and diabetes, including a $100 million upfront and up to $285 million in milestones plus royalties.

Financial highlights

• SkyTrofa Q3 2024 revenue was EUR 47.2 million, flat year-over-year due to higher sales deductions despite >60% volume growth; nine-month revenue reached EUR 138.5 million, up 21% year-over-year.

• YorviPath ex-U.S. Q3 revenue grew over 60% to EUR 8.5 million.

• Total Q3 revenue was EUR 57.8 million, up from EUR 48.0 million in Q3 2023.

• R&D expenses declined 34% year-over-year to EUR 73.5 million; SG&A rose to EUR 69.8 million due to commercial expansion.

• Ended Q3 with EUR 625.5 million in cash and equivalents, not including the expected $100 million Novo Nordisk upfront payment.

Outlook and guidance

• SkyTrofa full-year 2024 revenue guidance (excluding prior period sales deductions): EUR 200–220 million.

• Total 2024 operating expenses (SG&A and R&D) expected to be approximately EUR 600 million, including YorviPath U.S. launch costs.

• Expect to reach operating cash flow break-even by end of 2025.

• Anticipate sequential Q4 revenue growth for SkyTrofa, driven by stable pricing and increasing demand.

• Topline results from Phase 2 New InsiGHTS Trial in Turner syndrome expected Q4 2024; COACH trial data expected Q2 2025.